XTLB (XTL Biopharmaceuticals) Total Current Liabilities: $0.76 Mil (As of Jun. 2025)


XTLB XTL Biopharmaceuticals Ltd XTLB
26 GF Score
Price $2.38
! 2 Warning Signs
View Full Analysis

What is XTL Biopharmaceuticals Total Current Liabilities?

XTL Biopharmaceuticals XTLB +0.85% 26 Total Current Liabilities is $0.76 Mil as of Jun. 2025. GuruFocus rates XTLB with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. XTL Biopharmaceuticals's total current liabilities for the quarter that ended in Jun. 2025 was $0.76

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

XTL Biopharmaceuticals Total Current Liabilities Related Terms

XTL Biopharmaceuticals Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for XTL Biopharmaceuticals's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XTL Biopharmaceuticals Total Current Liabilities Chart

XTL Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.23 0.19 0.21 2.21

XTL Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.21 0.17 2.21 0.76
XTLB
26GF Score
XTL Biopharmaceuticals Ltd XTLB
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XTL Biopharmaceuticals Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

XTL Biopharmaceuticals's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.719+0.138
+Other Current Liabilities+Current Deferred Liabilities
=1.332+0.018
=2.21

XTL Biopharmaceuticals's Total Current Liabilities for the quarter that ended in Jun. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.638+0.086
+Other Current Liabilities+Current Deferred Liabilities
=0.037+0
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $0.76 Mil mean?
XTL Biopharmaceuticals (XTLB) has a Total Current Liabilities of $0.76 Mil as of Jun. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for XTL Biopharmaceuticals and its competitors.
Is XTL Biopharmaceuticals' Total Current Liabilities too high?
XTL Biopharmaceuticals' current Total Current Liabilities is $0.76 Mil. Overall, XTL Biopharmaceuticals has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' Total Current Liabilities compare to VRTX and REGN?
XTL Biopharmaceuticals' Total Current Liabilities of $0.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current Total Current Liabilities is $0.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current Total Current Liabilities of $0.76 Mil. The current Total Current Liabilities is $0.76 Mil. XTL Biopharmaceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current Total Current Liabilities is $0.76 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XTL Biopharmaceuticals Business Description

Other Exchanges XTLB:IsraelHHB0:Germany
Address 26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
26GF Score

Get the complete analysis for XTLB

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.38
Price